gptkbp:instanceOf
|
gptkb:drug
|
gptkbp:approvalYear
|
2016
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
gptkbp:ATCCode
|
gptkb:A05AA04
|
gptkbp:CASNumber
|
gptkb:459789-99-2
|
gptkbp:chemicalFormula
|
C26H44O4
|
gptkbp:contraindication
|
complete biliary obstruction
|
gptkbp:drugBank_ID
|
gptkb:DB11599
|
gptkbp:form
|
gptkb:tablet
|
gptkbp:genericName
|
gptkb:obeticholic_acid
|
gptkbp:hasBoxedWarning
|
true
risk of serious liver injury in some patients
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ocaliva
|
gptkbp:indication
|
gptkb:primary_biliary_cholangitis
treatment of adults with primary biliary cholangitis (PBC) with an inadequate response to or intolerance to ursodeoxycholic acid
|
gptkbp:isApprovedDrug
|
true
|
gptkbp:KEGGID
|
D10541
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:manufacturer
|
gptkb:Intercept_Pharmaceuticals
|
gptkbp:mechanismOfAction
|
farnesoid X receptor agonist
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
gptkbp:PubChem_CID
|
11559236
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
abdominal pain
fatigue
pruritus
rash
arthralgia
oropharyngeal pain
|
gptkbp:UNII
|
6ZY7X42A4I
|
gptkbp:bfsParent
|
gptkb:obeticholic_acid
gptkb:奥贝胆酸
|
gptkbp:bfsLayer
|
6
|